Q32 Bio, Inc. operates as a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. The company is headquartered in Waltham, Massachusetts and currently employs 27 full-time employees. The company went IPO on 2018-03-28. The company focuses on developing novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. Bempikibart (ADX-914), its advanced product candidate, is a fully human anti-interleukin-7 receptor alpha (IL-7Rα), an antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 (IL-7), and thymic stromal lymphopoietin (TSLP). The company has completed two Phase IIa clinical trials evaluating bempikibart, SIGNAL-AA for the treatment of alopecia areata (AA), and SIGNAL-AD for the treatment of atopic dermatitis (AD). ADX-097, a Phase 2 asset and the lead product candidate from its complement inhibitor platform, is a humanized anti-C3d monoclonal antibody, fusion protein.
Follow-Up Questions
Who is the CEO of Q32 Bio Inc?
Ms. Jodie Morrison is the Chief Executive Officer of Q32 Bio Inc, joining the firm since 2024.
What is the price performance of QTTB stock?
The current price of QTTB is $1.84, it has decreased 0.27% in the last trading day.
What are the primary business themes or industries for Q32 Bio Inc?
Q32 Bio Inc belongs to Biotechnology industry and the sector is Health Care
What is Q32 Bio Inc market cap?
Q32 Bio Inc's current market cap is $22.5M
Is Q32 Bio Inc a buy, sell, or hold?
According to wall street analysts, 6 analysts have made analyst ratings for Q32 Bio Inc, including 3 strong buy, 3 buy, 4 hold, 0 sell, and 3 strong sell
